Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies
Autore:
Schultz, H; Weiss, J; Carroll, SF; Gross, WL;
Indirizzi:
Med Univ Lubeck, Rheumaklin Bad Bramstedt GmbH, Dept Rheumatol, D-24572 Bad Bramstedt, Germany Med Univ Lubeck Bad Bramstedt Germany D-24572 572 Bad Bramstedt, Germany Univ Iowa, Div Infect Dis, Dept Internal Med, Iowa City, IA USA Univ IowaIowa City IA USA ect Dis, Dept Internal Med, Iowa City, IA USA VAMC, Iowa City, IA USA VAMC Iowa City IA USAVAMC, Iowa City, IA USA XOM US LLC, Preclin Res, Berkeley, CA USA XOM US LLC Berkeley CA USAXOM US LLC, Preclin Res, Berkeley, CA USA
Titolo Testata:
JOURNAL OF LEUKOCYTE BIOLOGY
fascicolo: 4, volume: 69, anno: 2001,
pagine: 505 - 512
SICI:
0741-5400(200104)69:4<505:TEBP(A>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; AMINO-TERMINAL FRAGMENT; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; INFLAMMATORY BOWEL-DISEASE; SYSTEMIC LUPUS-ERYTHEMATOSUS; SEVERE MENINGOCOCCAL SEPSIS; APOPTOTIC CELL CLEARANCE; INDUCED CYTOKINE RELEASE; GRAM-NEGATIVE BACTERIA; LIPOPOLYSACCHARIDE-BINDING;
Keywords:
anti-neutrophil cytoplasmic autoantibodies neutrophil granule proteins; gram-negative bacteria; lipopolysaccharides;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
87
Recensione:
Indirizzi per estratti:
Indirizzo: Schultz, H Med Univ Lubeck, Rheumaklin Bad Bramstedt GmbH, Dept Rheumatol,POB 1448, D-24572 Bad Bramstedt, Germany Med Univ Lubeck POB 1448 Bad Bramstedt Germany D-24572 Germany
Citazione:
H. Schultz et al., "The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies", J LEUK BIOL, 69(4), 2001, pp. 505-512

Abstract

The bactericidal/permeability-increasing protein (BPI) is an endotoxin-binding neutrophil leukocyte-granule protein with antibacterial and anti-endotoxin properties. A recombinant form of BPI (rBPI(21)) has been developed and is being tested as a therapeutic agent to treat Gram-negative bacterial infections and exposure to Gram-negative bacterial endotoxin, BPI is also a target antigen of anti-neutrophil cytoplasmic autoantibodies (ANCA). BPI-ANCA are present in cystic fibrosis, inflammatory bowel disease, vasculitis, and primary sclerosing cholangitis; presence of BPI-ANCA appears associatedwith a higher inflammatory disease activity and greater organ damage. BPI-ANCA as well as ANCA directed at other neutrophil-granule proteins may exacerbate inflammation by nonspecific effects of extracellular and cell-associated immune complexes. BPI-ANCA may further worsen inflammation by reducingthe ability of BPI to promote clearance of Gram-negative bacteria and bacterial-associated endotoxin.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 21:22:33